(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Olfaction Disorders D000857 17 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Body Weight D001835 333 associated lipids
Brain Diseases D001927 27 associated lipids
Celiac Disease D002446 16 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Chondrodysplasia Punctata D002806 8 associated lipids
Chronic Disease D002908 7 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Edema D004487 152 associated lipids
Exostoses, Multiple Hereditary D005097 3 associated lipids
Fasciitis D005208 2 associated lipids
Fatigue D005221 10 associated lipids
Fibrosarcoma D005354 8 associated lipids
Gallbladder Diseases D005705 3 associated lipids
Hemolysis D006461 131 associated lipids
Hepatitis D006505 11 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Hyperlipoproteinemia Type III D006952 4 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Keloid D007627 12 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Leukemia, Hairy Cell D007943 5 associated lipids
Lipodystrophy D008060 4 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuroblastoma D009447 66 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Bhilwade HN et al. Squalene as novel food factor. 2010 Curr Pharm Biotechnol pmid:20874681
Iannitti T and Palmieri B An update on the therapeutic role of alkylglycerols. 2010 Mar Drugs pmid:20948908
Voyron S et al. Antifungal activity of bis-azasqualenes, inhibitors of oxidosqualene cyclase. 2010 Mycoses pmid:19549106
Khurana S et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. 2010 Sci Transl Med pmid:20371470
Lippi G et al. Vaccination, squalene and anti-squalene antibodies: facts or fiction? 2010 Eur. J. Intern. Med. pmid:20206873
Barnett SW et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. 2010 J. Virol. pmid:20392857
Caron J et al. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. 2010 Bioorg. Med. Chem. Lett. pmid:20363623
Xiong Z et al. A short total synthesis of (+)-omaezakianol via an epoxide-initiated cationic cascade reaction. 2010 Org. Lett. pmid:20218639
Durando P et al. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. 2010 Expert Opin Biol Ther pmid:20218923
Taramino S et al. Interactions of oxidosqualene cyclase (Erg7p) with 3-keto reductase (Erg27p) and other enzymes of sterol biosynthesis in yeast. 2010 Biochim. Biophys. Acta pmid:19879375
van Himbergen TM et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. 2010 Arterioscler. Thromb. Vasc. Biol. pmid:19834104
Keitel W et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. 2010 Vaccine pmid:19835829
Brunner R et al. The ABC of clinical and experimental adjuvants--a brief overview. 2010 Immunol. Lett. pmid:19895847
Eroglu E and Melis A Extracellular terpenoid hydrocarbon extraction and quantitation from the green microalgae Botryococcus braunii var. Showa. 2010 Bioresour. Technol. pmid:20005092
Kalvodova L Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. 2010 Biochem. Biophys. Res. Commun. pmid:20018176
Kimura M et al. Protostadienol synthase from Aspergillus fumigatus: functional conversion into lanosterol synthase. 2010 Biochem. Biophys. Res. Commun. pmid:19951700
Yasuda Y et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. 2010 Adv Ther pmid:20586002
Frey SE et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. 2010 Vaccine pmid:20619382
Dosio F et al. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation. 2010 Bioconjug. Chem. pmid:20597546
Sarpietro MG et al. Interaction of acyclovir and its squalenoyl-acyclovir prodrug with DMPC in monolayers at the air/water interface. 2010 Int J Pharm pmid:20635474
Wohlrab J et al. Interaction of epicutaneously applied lipids with stratum corneum depends on the presence of either emulsifiers or hydrogenated phosphatidylcholine. 2010 Skin Pharmacol Physiol pmid:20523109
Koohang A et al. Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. 2010 J. Org. Chem. pmid:20545375
Camin F et al. Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane. 2010 Rapid Commun. Mass Spectrom. pmid:20499327
Mantzouridou F and Tsimidou MZ Observations on squalene accumulation in Saccharomyces cerevisiae due to the manipulation of HMG2 and ERG6. 2010 FEMS Yeast Res. pmid:20550581
Van Damme P et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. 2010 BMC Infect. Dis. pmid:20504306
Waddington CS et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. 2010 BMJ pmid:20508026
Beck F et al. Queries about vaccines containing squalene. 2010 Immunol. Cell Biol. pmid:20157330
Gerpe A et al. Naftifine-analogues as anti-Trypanosoma cruzi agents. 2010 Eur J Med Chem pmid:20163894
Warleta F et al. Squalene protects against oxidative DNA damage in MCF10A human mammary epithelial cells but not in MCF7 and MDA-MB-231 human breast cancer cells. 2010 Food Chem. Toxicol. pmid:20138105
Sugihara N et al. Novel fractionation method for squalene and phytosterols contained in the deodorization distillate of rice bran oil. 2010 J Oleo Sci pmid:20103978
Chen CC et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. 2010 Eur J Pharm Biopharm pmid:20060469
Spanova M et al. Effect of lipid particle biogenesis on the subcellular distribution of squalene in the yeast Saccharomyces cerevisiae. 2010 J. Biol. Chem. pmid:20032462
Tsai T et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. 2010 Vaccine pmid:19969117
Pietrella D et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. 2010 Vaccine pmid:20038431
Gasparini R et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. 2010 Int. J. Clin. Pract. pmid:20039974
Narayan BH et al. Modulation of doxorubicin-induced genotoxicity by squalene in Balb/c mice. 2010 Food Funct pmid:21776469
Bildstein L et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. 2010 J Control Release pmid:20691740
Weiss TL et al. Raman spectroscopy analysis of botryococcene hydrocarbons from the green microalga Botryococcus braunii. 2010 J. Biol. Chem. pmid:20705610
Nakagawa K et al. gamma-Tocotrienol reduces squalene hydroperoxide-induced inflammatory responses in HaCaT keratinocytes. 2010 Lipids pmid:20714817
Black S et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. 2010 Vaccine pmid:20813217
Lin FY et al. Mechanism of action and inhibition of dehydrosqualene synthase. 2010 Proc. Natl. Acad. Sci. U.S.A. pmid:21098670
Ali NA et al. Essential oil composition of leaves of Stachys yemenensis obtained by supercritical COâ‚‚. 2010 Nat. Prod. Res. pmid:21104527
Walker WT and Faust SN Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. 2010 Expert Rev Vaccines pmid:21105775
Beran J et al. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. 2010 Clin Ther pmid:21316535
El Sahly H MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. 2010 Expert Rev Vaccines pmid:20923265
Waddington C et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. 2010 Health Technol Assess pmid:20923610
Reddy LH et al. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. 2009 Sep-Oct Mol. Pharm. pmid:19634915
Huang MH et al. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. 2009 May-Jun Microbes Infect. pmid:19344782
Kopena R et al. Lipophilic compounds from the femoral gland secretions of male Hungarian green lizards, Lacerta viridis. 2009 May-Jun Z. Naturforsch., C, J. Biosci. pmid:19678551
Seiki S and Frishman WH Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. 2009 Mar-Apr Cardiol Rev pmid:19367148